Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SKAN Group AGFRA:7VG +4.13%66 Return-on-Tangible-Asset is 11.96% as of Dec. 2025, which is 161% above its 10-year median of 4.58. GuruFocus rates FRA:7VG with a GF Score™ of 66/100 and a GF Value™ of €91.09 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 857 Medical Devices & Instruments companies, SKAN Group AG ranks better than 62.66% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. SKAN Group AG's annualizedNet Income for the quarter that ended in Dec. 2025 was €54.0 Mil. SKAN Group AG's average total tangible assets for the quarter that ended in Dec. 2025 was €451.2 Mil. Therefore, SKAN Group AG's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was 11.96%.
The historical rank and industry rank for SKAN Group AG's Return-on-Tangible-Asset or its related term are showing as below:
FRA:7VG'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 1.76 Med: 4.58 Max: 10.33
Current: 3.99
During the past 6 years, SKAN Group AG's highest Return-on-Tangible-Asset was 10.33%. The lowest was 1.76%. And the median was 4.58%.
FRA:7VG's Return-on-Tangible-Asset is ranked better than 62.66% of 857
companies
in the Medical Devices & Instruments industry
Industry Median: 0.57
vs FRA:7VG: 3.99
SKAN Group AG (FRA:7VG) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
SKAN Group AG Return-on-Tangible-Asset Related Terms
SKAN Group AG Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for SKAN Group AG's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:7VG vs ISRG, BDX, MDLN: Return-on-Tangible-Asset Comparison
For the Medical Instruments & Supplies subindustry, SKAN Group AG's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SKAN Group AG Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, SKAN Group AG's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where SKAN Group AG's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of 11.96% mean?
SKAN Group AG (FRA:7VG) has a Return-on-Tangible-Asset of 11.96% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on SKAN Group AG and its competitors. This is 161% above median its historical median of 4.58. Over the past decade, SKAN Group AG's Return-on-Tangible-Asset has ranged from 1.76 to 10.33. According to the industry distribution chart, SKAN Group AG ranks #320 out of 857 companies in the Medical Devices & Instruments industry, placing it in the top 37.3%.
Is SKAN Group AG's Return-on-Tangible-Asset too high?
SKAN Group AG's current Return-on-Tangible-Asset of 11.96% is 161% above median its 10-year median of 4.58. Over the past 10 years, this metric has ranged from a low of 1.76 to a high of 10.33. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.57. SKAN Group AG's value of 11.96% is 1998.2% above this industry median. Based on the distribution chart, SKAN Group AG ranks #320 out of 857 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, SKAN Group AG has a GF Score™ of 66/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does SKAN Group AG's Return-on-Tangible-Asset compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, SKAN Group AG ranks #320 out of 857 companies for Return-on-Tangible-Asset. This puts SKAN Group AG in the upper half of its industry. The industry median Return-on-Tangible-Asset is 0.57. SKAN Group AG's value of 11.96% is 1998.2% above this benchmark. Historically, SKAN Group AG's own Return-on-Tangible-Asset has ranged from 1.76 to 10.33 over the past decade. While the company's 10-year median is 4.58 vs. the industry median of 0.57, SKAN Group AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.57, based on 857 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SKAN Group AG's current Return-on-Tangible-Asset of 11.96% is 1998.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on SKAN Group AG and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SKAN Group AG's current Return-on-Tangible-Asset is 11.96%, which is 161% above median its own 10-year median of 4.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SKAN Group AG stock overvalued right now?
Based on GuruFocus' analysis, SKAN Group AG (FRA:7VG) is currently considered Significantly Undervalued. The stock's GF Value™ is €91.09, compared to a current price of €63.00 — trading 30.8% below its estimated fair value. The current Return-on-Tangible-Asset is 11.96%, which is 161% above median its 10-year median of 4.58 and 1998.2% above the Medical Devices & Instruments industry median of 0.57. SKAN Group AG's overall GF Score™ is 66/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For SKAN Group AG (FRA:7VG), the current Return-on-Tangible-Asset is 11.96% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SKAN Group AG (FRA:7VG) Overvalued in 2026?
Based on GuruFocus' analysis, SKAN Group AG stock appears to be undervalued.
The current stock price of €63.00 is trading 30.8% below its estimated GF Value™ of €91.09.
GuruFocus considers SKAN Group AG to be Significantly Undervalued.
Key valuation signals for FRA:7VG:
Return-on-Tangible-Asset: 11.96% (161% above median its 10-year median of 4.58)
GF Value™: €91.09 vs. price of €63.00 (30.8% below fair value)
Industry Position: 1998.2% above the Medical Devices & Instruments median (#320 of 857)
No single metric tells the full story. See the FRA:7VG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SKAN Group AG is a market and technological company for isolators, cleanroom devices, and decontamination processes for the aseptic production of biopharmaceutical substances. The company offers its customers process support, services, and consumables. Its products include biological indicators, isolators, Laboratory/cleanroom equipment, laminar flow, safety workbenches, transfer systems, and others. The Firm has three operating segments: Equipment & solutions, Services & Consumables, and Other. The company generates the majority of its revenue from the Equipment & solutions segment. Geographically, the company derives revenue from Asia, Europe, Americas, and Other regions.
66GF Score
Get the complete analysis for FRA:7VG
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7VG has been successfully added to your 
